FindTrial
Sign In

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511510-20-00
Enrollment
5
Registered
2026-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

craniopharyngioma

Brief summary

PFS12 (progression free survival at 12 months), QOL12 (quality of life at 12 months)

Detailed description

Visual Responsive ≥ 0.2 logMAR improvement in VA compared to baseline, Stable VA = does not meet criteria for Improved or Worsening VA compared to baseline, Visual Progressive Disease ≥ 0.2 logMAR worsening compared to baseline, Visual field assessments with Humphrey visual field test, Presence or absence of new from baseline: hypothalamic obesity, diabetes insipidus, growth hormone deficiency, adrenal insufficiency

Interventions

DRUGTovorafenib

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V.
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
PFS12 (progression free survival at 12 months), QOL12 (quality of life at 12 months)—

Secondary

MeasureTime frame
Visual Responsive ≥ 0.2 logMAR improvement in VA compared to baseline, Stable VA = does not meet criteria for Improved or Worsening VA compared to baseline, Visual Progressive Disease ≥ 0.2 logMAR worsening compared to baseline, Visual field assessments with Humphrey visual field test, Presence or absence of new from baseline: hypothalamic obesity, diabetes insipidus, growth hormone deficiency, adrenal insufficiency—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 26, 2026